SCHEMBL13627938

SCHEMBL13627938

O=C1/C(=N\O)c2cc(F)ccc2N1Cc1ccc([N+](=O)[O-])cc1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CA12 O43570 3/20 0.52
▸ CA1 P00915 3/20 0.52
▸ CA2 P00918 3/20 0.52
▸ CA9 Q16790 3/20 0.52
▸ ALDH1A1 P00352 6/20 0.50
▸ MAPT P10636 3/20 0.50
▸ CASP3 P42574 2/20 0.50
▸ CASP7 P55210 2/20 0.50
▸ HPGD P15428 2/20 0.50
▸ HTT P42858 2/20 0.50
▸ MEN1 O00255 1/20 0.50
▸ NPC1 O15118 1/20 0.50
▸ LMNA P02545 1/20 0.50
▸ RAB9A P51151 1/20 0.50
▸ KMT2A Q03164 1/20 0.50
▸ SMN1; SMN2 Q16637 1/20 0.50
▸ CASP1 P29466 1/20 0.50
▸ CASP4 P49662 1/20 0.50
▸ CASP9 P55211 1/20 0.50
▸ CASP6 P55212 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13627911 0.93 CASP3 (0.56) CA12CA1CA2CA9ALDH1A1
SCHEMBL13627972 0.88 ALDH1A1 (0.57) CA12CA1CA2CA9ALDH1A1
SCHEMBL13627937 0.88 CHRM5 (0.55) CA12CA1CA2CA9ALDH1A1
SCHEMBL13627920 0.86 MAPT (0.52) CA12CA1CA2CA9ALDH1A1
SCHEMBL13627904 0.86 ACHE (0.53) CA12CA1CA2CA9ALDH1A1
SCHEMBL13627915 0.86 CASP1 (0.56) CA12CA1CA2CA9ALDH1A1
SCHEMBL13627887 0.85 MAPT (0.66) CA12CA1CA2CA9ALDH1A1
SCHEMBL13627912 0.84 MAPT (0.57) CA12CA1CA2CA9ALDH1A1
SCHEMBL13627910 0.84 CASP1 (0.72) CA12CA1CA2CA9ALDH1A1
SCHEMBL13627895 0.83 MAPT (0.58) CA12CA1CA2CA9ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7612065-B2 Inhibitors of c-JUN N-terminal kinases (JNK) VERTEX PHARMACEUTICALS INCORPORATED (US) 2009-11-03 — — US disclosed
US-20080033022-A1 Inhibitors of c-Jun N-terminal kinases (JNK) SALITURO FRANCESCO G 2008-02-07 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080033022-A1 Inhibitors of c-Jun N-terminal kinases (JNK) MAP3K1, JUN, MAP3K7 CA12 4791/4885CA1 3628/4885CA2 3142/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback